Mechanisms of NAFLD development and therapeutic strategies

被引：3288

作者：

Friedman, Scott L. ^{[1
]}

Neuschwander-Tetri, Brent A. ^{[2
]}

Rinella, Mary ^{[3
]}

Sanyal, Arun J. ^{[4
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA

[2] St Louis Univ Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA

[3] Northwestern Univ, Div Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Virginia Commonwealth Univ, Div Gastroenterol, Richmond, VA USA

来源：

NATURE MEDICINE | 2018年 / 24卷 / 07期

关键词：

NONALCOHOLIC FATTY LIVER; TISSUE INSULIN-RESISTANCE; DE-NOVO LIPOGENESIS; TERM-FOLLOW-UP; ADIPOSE-TISSUE; HEPATIC STEATOSIS; CARDIOVASCULAR-DISEASE; DIETARY FRUCTOSE; MOUSE MODEL; WEIGHT-LOSS;

D O I：

10.1038/s41591-018-0104-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.

引用

页码：908 / 922

页数：15

共 179 条

[1]

Abdelmalek M. F., 2017, J HEPATOL, V67, P1265

[2] A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease [J].

Abul-Husn, N. S. ;

Cheng, X. ;

Li, A. H. ;

Xin, Y. ;

Schurmann, C. ;

Stevis, P. ;

Liu, Y. ;

Kozlitina, J. ;

Stender, S. ;

Wood, G. C. ;

Stepanchick, A. N. ;

Still, M. D. ;

McCarthy, S. ;

O'Dushlaine, C. ;

Packer, J. S. ;

Balasubramanian, S. ;

Gosalia, N. ;

Esopi, D. ;

Kim, S. Y. ;

Mukherjee, S. ;

Lopez, A. E. ;

Fuller, E. D. ;

Penn, J. ;

Chu, X. ;

Luo, J. Z. ;

Mirshahi, U. L. ;

Carey, D. J. ;

Still, C. D. ;

Feldman, M. D. ;

Small, A. ;

Damrauer, S. M. ;

Rader, D. J. ;

Zambrowicz, B. ;

Olson, W. ;

Murphy, A. J. ;

Borecki, I. B. ;

Shuldiner, A. R. ;

Reid, J. G. ;

Overton, J. D. ;

Yancopoulos, G. D. ;

Hobbs, H. H. ;

Cohen, J. C. ;

Gottesman, O. ;

Teslovich, T. M. ;

Baras, A. ;

Mirshahi, T. ;

Gromada, J. ;

Dewey, F. E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1096-1106

[3] The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies [J].

Adams, LA ;

Sanderson, S ;

Lindor, KD ;

Angulo, P .

JOURNAL OF HEPATOLOGY, 2005, 42 (01) :132-138

[4] ERRγ Preserves Brown Fat Innate Thermogenic Activity [J].

Ahmadian, Maryam ;

Liu, Sihao ;

Reilly, Shannon M. ;

Hah, Nasun ;

Fan, Weiwei ;

Yoshihara, Eiji ;

Jha, Pooja ;

De Magalhaes Filho, C. Daniel ;

Jacinto, Sandra ;

Gomez, Andrew V. ;

Dai, Yang ;

Yu, Ruth T. ;

Liddle, Christopher ;

Atkins, Annette R. ;

Auwerx, Johan ;

Saltiel, Alan R. ;

Downes, Michael ;

Evans, Ronald M. .

CELL REPORTS, 2018, 22 (11) :2849-2859

[5]

Alkhouri N, 2011, EXPERT REV GASTROENT, V5, P201, DOI [10.1586/egh.11.6, 10.1586/EGH.11.6]

[6] Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study [J].

Allen, Alina M. ;

Therneau, Terry M. ;

Larson, Joseph J. ;

Coward, Alexandra ;

Somers, Virend K. ;

Kamath, Patrick S. .

HEPATOLOGY, 2018, 67 (05) :1726-1736

[7] Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis [J].

Alonso, Cristina ;

Fernandez-Ramos, David ;

Varela-Rey, Marta ;

Martinez-Arranz, Ibon ;

Navasa, Nicolas ;

Van Liempd, Sebastiaan M. ;

Lavin Trueba, Jose L. ;

Mayo, Rebeca ;

Ilisso, Concetta P. ;

de Juan, Virginia G. ;

Iruarrizaga-Lejarreta, Marta ;

delaCruz-Villar, Laura ;

Minchole, Itziar ;

Robinson, Aaron ;

Crespo, Javier ;

Martin-Duce, Antonio ;

Romero-Gomez, Manuel ;

Sann, Holger ;

Platon, Julian ;

Van Eyk, Jennifer ;

Aspichueta, Patricia ;

Noureddin, Mazen ;

Falcon-Perez, Juan M. ;

Anguita, Juan ;

Aransay, Ana M. ;

Luz Martinez-Chantar, Maria ;

Lu, Shelly C. ;

Mato, Jose M. .

GASTROENTEROLOGY, 2017, 152 (06) :1449-+

[8]

Alvarado Tamara Feliciano, 2016, Gene Expression, V17, P19, DOI 10.3727/105221616X691631

[9] Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].

Angulo, P ;

Keach, JC ;

Batts, KP ;

Lindor, KD .

HEPATOLOGY, 1999, 30 (06) :1356-1362

[10] Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].

Angulo, Paul ;

Kleiner, David E. ;

Dam-Larsen, Sanne ;

Adams, Leon A. ;

Bjornsson, Einar S. ;

Charatcharoenwitthaya, Phunchai ;

Mills, Peter R. ;

Keach, Jill C. ;

Lafferty, Heather D. ;

Stahler, Alisha ;

Haflidadottir, Svanhildur ;

Bendtsen, Flemming .

GASTROENTEROLOGY, 2015, 149 (02) :389-+

← 1 2 3 4 5 6 7 8 9 10 →